Published in Cochrane Database Syst Rev on January 01, 2004
Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype? Respir Res (2006) 1.51
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol (2015) 1.42
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol (2012) 1.40
Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol (2012) 1.23
Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91
Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J Gastroenterol (2010) 0.89
Laparoscopic surgery for inflammatory bowel disease: does weight matter? Surg Endosc (2010) 0.89
The development and assessment of biological treatments for children. Br J Clin Pharmacol (2015) 0.89
Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci (2009) 0.83
Antioxidative potential of a combined therapy of anti TNFα and Zn acetate in experimental colitis. World J Gastroenterol (2011) 0.82
Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics (2009) 0.81
In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. ISRN Gastroenterol (2012) 0.79
Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery. J Biomed Mater Res B Appl Biomater (2009) 0.79
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease. Surg Today (2015) 0.78
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther (2017) 0.77
TNFα causes thrombin-dependent vagal neuron apoptosis in inflammatory bowel disease. J Gastrointest Surg (2014) 0.77
Change in the treatment strategy for pediatric Crohn's disease. Korean J Pediatr (2010) 0.77
Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease. Medicine (Baltimore) (2016) 0.76
Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in rats. Dig Dis Sci (2008) 0.76
Crohn's disease. BMJ Clin Evid (2007) 0.75
Time of infliximab therapy initiation and dose escalation in Crohn's disease. World J Gastroenterol (2014) 0.75
Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. Am J Gastroenterol (2016) 0.75
Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr (2001) 1.39
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev (2005) 1.05
Gastral antral biopsy in the differentiation of pediatric colitides. Am J Gastroenterol (2003) 0.92
Purification of the testicular galactolipid: 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase. J Biol Chem (1992) 0.80
Pediatric Crohn Disease Activity Index: responsive to short-term change. J Pediatr Gastroenterol Nutr (2003) 0.80
Antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody: clinical tools or clues for research? J Pediatr Gastroenterol Nutr (2000) 0.75